{"id":"W3008727692","doi":"10.1200/jco.2020.38.6_suppl.tps768","title":"UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Immune checkpoint; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006585593,0.0006362179,0.0007632508,0.0002266346,0.0002680547,0.0005918226,0.0005287938,0.000990783,0.02065622],"category_scores_gemma":[0.0004043223,0.0002934341,0.0007357432,0.0001812405,0.0002055824,0.0006641143,0.0003364405,0.001340031,0.002589806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007489049,"about_ca_system_score_gemma":0.0009754954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00115845,"about_ca_topic_score_gemma":0.005582035,"domain_scores_codex":[0.9998659,0.00004587771,0.000008212722,0.00002903726,0.00001332328,0.00003754868],"domain_scores_gemma":[0.9998502,0.00001904585,0.00002408476,0.000008965568,0.00001215563,0.00008556266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5332251,0.01262022,0.004419636,0.002597616,0.00106604,0.0001743058,0.0001728635,0.001349963,0.01394592,0.001025388,0.03602783,0.3933751],"study_design_scores_gemma":[0.6754276,0.2252795,0.01908292,0.0005695869,0.001248543,0.0005469379,0.0001414888,0.001867245,0.004732283,0.0008544601,0.07020244,0.00004694487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9287744,0.01837492,0.0007157677,0.003448023,0.001975228,0.00615107,0.005247149,0.0005796612,0.03473382],"genre_scores_gemma":[0.9551213,0.005122617,0.002025803,0.003084804,0.0003822325,0.004770929,0.003658179,0.00007009909,0.02576411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02065622,"threshold_uncertainty_score":0.06910199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09471171853521936,"score_gpt":0.3862995334017595,"score_spread":0.2915878148665402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}